Evaluation of the impact of customized serum-free culture medium on the production of clinical-grade human umbilical cord mesenchymal stem cells: insights for future clinical applications.
SFM
Stem cell therapy
hUC-MSCs
Journal
Stem cell research & therapy
ISSN: 1757-6512
Titre abrégé: Stem Cell Res Ther
Pays: England
ID NLM: 101527581
Informations de publication
Date de publication:
27 Sep 2024
27 Sep 2024
Historique:
received:
26
06
2024
accepted:
18
09
2024
medline:
28
9
2024
pubmed:
28
9
2024
entrez:
28
9
2024
Statut:
epublish
Résumé
The selection of suitable culture medium is critical for achieving good clinical outcomes in cell therapy. To support the commercial application of stem cell therapy, customized culture media not only need to promote stem cell proliferation, but also need to save costs and meet industrial requirements for inter-batch consistency, efficacy, and biosafety. In this study, we developed a series of serum-free media (SFM) and elucidated the effects between different SFM, as well as between SFM and serum-containing meida (SCM), on human umbilical cord mesenchymal stem cells (hUC-MSCs) phenotype and function. We analyze and emphasize from the perspectives of clinical and commercial application why research on customized culture media is critical for the success of enterprises developing novel cellular therapeutics. We cultured hUC-MSCs with identical cell seeding densities in different formulations of SFM and SCM until passage 10 and examined the changes in cell phenotype and function. We analyzed the results with the commercial application requirments of the cellular therapy industry to assess the potential impact of customized culture media on inter-batch consistency, efficacy, stability, biosafety, and cost-effectiveness of industrial-scale cell production. hUC-MSCs cultured in SCM and SFM exhibit consistent cell morphology and surface molecule expression, but hUC-MSCs cultured in SFM demonstrate higher activity, superior proliferative capacity, and greater stability. Furthermore, hUC-MSCs cultured in different SFM exhibit differences in cell activity, proliferative capacity, senescent rate, and S/M ratio of cell cycle, while maintaining a normal karyotype after long-term in vitro cultivation. Moreover, we found that hUC-MSCs cultured in different media exhibit variations in paracrine capacity and in their support of hematopoietic stem cell (HSC) self-renewal. Considering the substantial funding and time required for cell-based drug development, our results underscore the importances of comprehensively optimizing the composition of medium for the specific disease prior to conducting clinical trials of cell-based therapies. The criteria for selecting culture medium should be based on the requirements of the target disease for cellular function. In addition, we provide a way to formulate different customized SFM, which is beneficial for the development of cell therapy industry.
Sections du résumé
BACKGROUND
BACKGROUND
The selection of suitable culture medium is critical for achieving good clinical outcomes in cell therapy. To support the commercial application of stem cell therapy, customized culture media not only need to promote stem cell proliferation, but also need to save costs and meet industrial requirements for inter-batch consistency, efficacy, and biosafety. In this study, we developed a series of serum-free media (SFM) and elucidated the effects between different SFM, as well as between SFM and serum-containing meida (SCM), on human umbilical cord mesenchymal stem cells (hUC-MSCs) phenotype and function. We analyze and emphasize from the perspectives of clinical and commercial application why research on customized culture media is critical for the success of enterprises developing novel cellular therapeutics.
METHODS
METHODS
We cultured hUC-MSCs with identical cell seeding densities in different formulations of SFM and SCM until passage 10 and examined the changes in cell phenotype and function. We analyzed the results with the commercial application requirments of the cellular therapy industry to assess the potential impact of customized culture media on inter-batch consistency, efficacy, stability, biosafety, and cost-effectiveness of industrial-scale cell production.
RESULTS
RESULTS
hUC-MSCs cultured in SCM and SFM exhibit consistent cell morphology and surface molecule expression, but hUC-MSCs cultured in SFM demonstrate higher activity, superior proliferative capacity, and greater stability. Furthermore, hUC-MSCs cultured in different SFM exhibit differences in cell activity, proliferative capacity, senescent rate, and S/M ratio of cell cycle, while maintaining a normal karyotype after long-term in vitro cultivation. Moreover, we found that hUC-MSCs cultured in different media exhibit variations in paracrine capacity and in their support of hematopoietic stem cell (HSC) self-renewal.
CONCLUSION
CONCLUSIONS
Considering the substantial funding and time required for cell-based drug development, our results underscore the importances of comprehensively optimizing the composition of medium for the specific disease prior to conducting clinical trials of cell-based therapies. The criteria for selecting culture medium should be based on the requirements of the target disease for cellular function. In addition, we provide a way to formulate different customized SFM, which is beneficial for the development of cell therapy industry.
Identifiants
pubmed: 39334391
doi: 10.1186/s13287-024-03949-0
pii: 10.1186/s13287-024-03949-0
doi:
Substances chimiques
Culture Media, Serum-Free
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
327Subventions
Organisme : Science Assistance Project for Xinjiang
ID : 2024E02062
Organisme : National Natural Science Foundation of China
ID : 3239014
Organisme : National Natural Science Foundation of China
ID : 82304575
Organisme : Guangdong Provincial Basic and Applied Basic Research Fund
ID : 2022A1515110883
Organisme : Young Scientists Program of Guangzhou Laboratory
ID : No. QNPG24-09
Informations de copyright
© 2024. The Author(s).
Références
Li P, Ou Q, Shi S, Shao C. Immunomodulatory properties of mesenchymal stem cells/dental stem cells and their therapeutic applications. Cell Mol Immunol. 2023;20(6):558–69.
pubmed: 36973490
pmcid: 10040934
doi: 10.1038/s41423-023-00998-y
Izadi M, Sadr Hashemi Nejad A, Moazenchi M, Masoumi S, Rabbani A, Kompani F, Hedayati Asl AA, Abbasi Kakroodi F, Jaroughi N, Mohseni Meybodi MA, Setoodeh A, Abbasi F, Hosseini SE, Moeini Nia F, Salman Yazdi R, Navabi R, Hajizadeh-Saffar E, Baharvand H. Mesenchymal stem cell transplantation in newly diagnosed type-1 diabetes patients: a phase I/II randomized placebo-controlled clinical trial. Stem Cell Res Ther. 2022;13(1):264.
pubmed: 35725652
pmcid: 9208234
doi: 10.1186/s13287-022-02941-w
Li Q, Hou H, Li M, Yu X, Zuo H, Gao J, Zhang M, Li Z, Guo Z. CD73
doi: 10.3389/fcell.2021.637239
Nie M, Kong B, Chen G, Xie Y, Zhao Y, Sun L. MSCs-laden injectable self-healing hydrogel for systemic sclerosis treatment. Bioact Mater. 2022;19(17):369–78.
Wang W, Zhang M, Ren X, Song Y, Xu Y, Zhuang K, Xiao T, Guo X, Wang S, Hong Q, Feng Z, Chen X, Cai G. Single-cell dissection of cellular and molecular features underlying mesenchymal stem cell therapy in ischemic acute kidney injury. Mol Ther. 2023;31(10):3067–83.
pubmed: 37533253
doi: 10.1016/j.ymthe.2023.07.024
Beetler DJ, Di Florio DN, Law EW, Groen CM, Windebank AJ, Peterson QP, Fairweather D. The evolving regulatory landscape in regenerative medicine. Mol Aspects Med. 2023;91:101138.
pubmed: 36050142
doi: 10.1016/j.mam.2022.101138
López-Beas J, Guadix JA, Clares B, Soriano-Ruiz JL, Zugaza JL, Gálvez-Martín P. An overview of international regulatory frameworks for mesenchymal stromal cell-based medicinal products: from laboratory to patient. Med Res Rev. 2020;40(4):1315–34.
pubmed: 32017179
doi: 10.1002/med.21659
Al-Azab M, Idiiatullina E, Safi M, Hezam K. Enhancers of mesenchymal stem cell stemness and therapeutic potency. Biomed Pharmacother. 2023;162:114356.
pubmed: 37040673
doi: 10.1016/j.biopha.2023.114356
Mönch D, Reinders MEJ, Dahlke MH, Hoogduijn MJ. How to make sense out of 75,000 mesenchymal stromal cell publications? Cells. 2022;11(9):1419.
pubmed: 35563725
pmcid: 9101744
doi: 10.3390/cells11091419
Bahari M, Mokhtari H, Yeganeh F. Stem cell therapy, the market, the opportunities and the threat. Int J Mol Cell Med. 2023;12(3):310–9.
pubmed: 38751658
pmcid: 11092897
Hoang DM, Pham PT, Bach TQ, Ngo ATL, Nguyen QT, Phan TTK, Nguyen GH, Le PTT, Hoang VT, Forsyth NR, Heke M, Nguyen LT. Stem cell-based therapy for human diseases. Signal Transduct Target Ther. 2022;7(1):272.
pubmed: 35933430
pmcid: 9357075
doi: 10.1038/s41392-022-01134-4
Bui HTH, Nguyen LT, Than UTT. Influences of Xeno-free media on mesenchymal stem cell expansion for clinical application. Tissue Eng Regen Med. 2021;18(1):15–23.
pubmed: 33150562
doi: 10.1007/s13770-020-00306-z
Agostini F, Vicinanza C, Lombardi E, Da Ros F, Marangon M, Massarut S, Mazzucato M, Durante C. Ex vivo expansion in a clinical grade medium, containing growth factors from human platelets, enhances migration capacity of adipose stem cells. Front Immunol. 2024;14(15):1404228.
doi: 10.3389/fimmu.2024.1404228
Winkel A, Jaimes Y, Melzer C, Dillschneider P, Hartwig H, Stiesch M, von der Ohe J, Strauss S, Vogt PM, Hamm A, Burmeister L, Roger Y, Elger K, Floerkemeier T, Weissinger EM, Pogozhykh O, Müller T, Selich A, Rothe M, Petri S, Köhl U, Hass R, Hoffmann A. Cell culture media notably influence properties of human mesenchymal stroma/stem-like cells from different tissues. Cytotherapy. 2020;22(11):653–68.
pubmed: 32855067
doi: 10.1016/j.jcyt.2020.07.005
Nagasaki K, Nakashima A, Tamura R, Ishiuchi N, Honda K, Ueno T, Doi S, Kato Y, Masaki T. Mesenchymal stem cells cultured in serum-free medium ameliorate experimental peritoneal fibrosis. Stem Cell Res Ther. 2021;12(1):203.
pubmed: 33757592
pmcid: 7986267
doi: 10.1186/s13287-021-02273-1
Ullah I, Subbarao RB, Rho GJ. Human mesenchymal stem cells–current trends and future prospective. Biosci Rep. 2015;35(2):e00191.
pubmed: 25797907
pmcid: 4413017
doi: 10.1042/BSR20150025
Lv FJ, Tuan RS, Cheung KM, Leung VY. Concise review: the surface markers and identity of human mesenchymal stem cells. Stem Cells. 2014;32(6):1408–19.
pubmed: 24578244
doi: 10.1002/stem.1681
Mushahary D, Spittler A, Kasper C, Weber V, Charwat V. Isolation, cultivation, and characterization of human mesenchymal stem cells. Cytom A. 2018;93(1):19–31.
doi: 10.1002/cyto.a.23242
Ghaneialvar H, Soltani L, Rahmani HR, Lotfi AS, Soleimani M. Characterization and classification of mesenchymal stem cells in several species using surface markers for cell therapy purposes. Indian J Clin Biochem. 2018;33(1):46–52.
pubmed: 29371769
doi: 10.1007/s12291-017-0641-x
Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D, Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement. Cytotherapy. 2006;8(4):315–7.
pubmed: 16923606
doi: 10.1080/14653240600855905
Swamynathan P, Venugopal P, Kannan S, Thej C, Kolkundar U, Bhagwat S, Ta M, Majumdar AS, Balasubramanian S. Are serum-free and xeno-free culture conditions ideal for large scale clinical grade expansion of Wharton’s jelly derived mesenchymal stem cells? A comparative study. Stem Cell Res Ther. 2014;5(4):88.
pubmed: 25069491
pmcid: 4247668
doi: 10.1186/scrt477
Czapla J, Matuszczak S, Kulik K, Wiśniewska E, Pilny E, Jarosz-Biej M, Smolarczyk R, Sirek T, Zembala MO, Zembala M, Szala S, Cichoń T. The effect of culture media on large-scale expansion and characteristic of adipose tissue-derived mesenchymal stromal cells. Stem Cell Res Ther. 2019;10(1):235.
pubmed: 31383013
pmcid: 6683465
doi: 10.1186/s13287-019-1331-9
Piletz JE, Drivon J, Eisenga J, Buck W, Yen S, McLin M, Meruvia W, Amaral C, Brue K. Human cells grown with or without substitutes for fetal bovine serum. Cell Med. 2018;6(10):2155179018755140.
Selvaggi TA, Walker RE, Fleisher TA. Development of antibodies to fetal calf serum with arthus-like reactions in human immunodeficiency virus-infected patients given syngeneic lymphocyte infusions. Blood. 1997;89(3):776–9.
pubmed: 9028307
doi: 10.1182/blood.V89.3.776
Tuschong L, Soenen SL, Blaese RM, Candotti F, Muul LM. Immune response to fetal calf serum by two adenosine deaminase-deficient patients after T cell gene therapy. Hum Gene Ther. 2002;13(13):1605–10.
pubmed: 12228015
doi: 10.1089/10430340260201699
Santos Fd, Andrade PZ, Abecasis MM, Gimble JM, Chase LG, Campbell AM, Boucher S, Vemuri MC, Silva CL, Cabral JM. Toward a clinical-grade expansion of mesenchymal stem cells from human sources: a microcarrier-based culture system under xeno-free conditions. Tissue Eng Part C Methods. 2011;17(12):1201–10.
pubmed: 21895491
pmcid: 3226421
doi: 10.1089/ten.tec.2011.0255
Chase LG, Yang S, Zachar V, Yang Z, Lakshmipathy U, Bradford J, Boucher SE, Vemuri MC. Development and characterization of a clinically compliant xeno-free culture medium in good manufacturing practice for human multipotent mesenchymal stem cells. Stem Cells Transl Med. 2012;1(10):750–8.
pubmed: 23197667
pmcid: 3659659
doi: 10.5966/sctm.2012-0072
Bucar S, Branco ADM, Mata MF, Milhano JC, Caramalho Í, Cabral JMS, Fernandes-Platzgummer A, da Silva CL. Influence of the mesenchymal stromal cell source on the hematopoietic supportive capacity of umbilical cord blood-derived CD34
pubmed: 34256848
pmcid: 8278708
doi: 10.1186/s13287-021-02474-8
Denning-Kendall P, Singha S, Bradley B, Hows J. Cobblestone area-forming cells in human cord blood are heterogeneous and differ from long-term culture-initiating cells. Stem Cells. 2003;21(6):694–701.
pubmed: 14595129
doi: 10.1634/stemcells.21-6-694
Pal R, Hanwate M, Jan M, Totey S. Phenotypic and functional comparison of optimum culture conditions for upscaling of bone marrow-derived mesenchymal stem cells. J Tissue Eng Regen Med. 2009;3(3):163–74.
pubmed: 19229888
doi: 10.1002/term.143
Tonarova P, Lochovska K, Pytlik R, Hubalek KM. The impact of various culture conditions on human mesenchymal stromal cells metabolism. Stem Cells Int. 2021;1(2021):6659244.
Bhat S, Viswanathan P, Chandanala S, Prasanna SJ, Seetharam RN. Expansion and characterization of bone marrow derived human mesenchymal stromal cells in serum-free conditions. Sci Rep. 2021;11(1):3403.
pubmed: 33564114
pmcid: 7873235
doi: 10.1038/s41598-021-83088-1
Zhao K, Liu Q. The clinical application of mesenchymal stromal cells in hematopoietic stem cell transplantation. J Hematol Oncol. 2016;9(1):46.
pubmed: 27193054
pmcid: 4870746
doi: 10.1186/s13045-016-0276-z
Le Blanc K, Samuelsson H, Gustafsson B, Remberger M, Sundberg B, Arvidson J, Ljungman P, Lönnies H, Nava S, Ringdén O. Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia. 2007;21(8):1733–8.
pubmed: 17541394
doi: 10.1038/sj.leu.2404777
Zhao L, Chen S, Yang P, Cao H, Li L. The role of mesenchymal stem cells in hematopoietic stem cell transplantation: prevention and treatment of graft-versus-host disease. Stem Cell Res Ther. 2019;10(1):182.
pubmed: 31227011
pmcid: 6588914
doi: 10.1186/s13287-019-1287-9
Arango-Rodríguez ML, Mateus LC, Sossa CL, Becerra-Bayona SM, Solarte-David VA, Ochoa Vera ME, Viviescas LTG, Berrio AMV, Serrano SE, Vargas O, Isla AC, Benitez A, Rangel G. A novel therapeutic management for diabetes patients with chronic limb-threatening ischemia: comparison of autologous bone marrow mononuclear cells versus allogenic Wharton jelly-derived mesenchymal stem cells. Stem Cell Res Ther. 2023;14(1):221.
pubmed: 37626416
pmcid: 10464344
doi: 10.1186/s13287-023-03427-z
Pan L, Liu C, Liu Q, Li Y, Du C, Kang X, Dong S, Zhou Z, Chen H, Liang X, Chu J, Xu Y, Zhang Q. Human Wharton’s jelly-derived mesenchymal stem cells alleviate concanavalin A-induced fulminant hepatitis by repressing NF-κB signaling and glycolysis. Stem Cell Res Ther. 2021;12(1):496.
pubmed: 34503553
pmcid: 8427901
doi: 10.1186/s13287-021-02560-x
Cheng T, Ding S, Liu S, Li Y, Sun L. Human umbilical cord-derived mesenchymal stem cell therapy ameliorates lupus through increasing CD4
pubmed: 33391511
pmcid: 7738872
doi: 10.7150/thno.48080
Gupta A, Maffulli N, Rodriguez HC, Lee CE, Levy HJ, El-Amin SF 3rd. Umbilical cord-derived Wharton’s jelly for treatment of knee osteoarthritis: study protocol for a non-randomized, open-label, multi-center trial. J Orthop Surg Res. 2021;16(1):143.
pubmed: 33602286
pmcid: 7890617
doi: 10.1186/s13018-021-02300-0
Yip HK, Fang WF, Li YC, Lee FY, Lee CH, Pei SN, Ma MC, Chen KH, Sung PH, Lee MS. Human umbilical cord-derived mesenchymal stem cells for acute respiratory distress syndrome. Crit Care Med. 2020;48(5):e391–9.
pubmed: 32187077
doi: 10.1097/CCM.0000000000004285
Galbraith SC, Bhatia H, Liu H, et al. Media formulation optimization: current and future opportunities. Curr Opin Chem Eng. 2018;22:42–7.
doi: 10.1016/j.coche.2018.08.004
Wei Z, Batagov AO, Carter DR, Krichevsky AM. Fetal bovine serum RNA interferes with the cell culture derived extracellular RNA. Sci Rep. 2016;9(6):31175.
doi: 10.1038/srep31175
Gottipamula S, Muttigi MS, Kolkundkar U, Seetharam RN. Serum-free media for the production of human mesenchymal stromal cells: a review. Cell Prolif. 2013;46(6):608–27.
pubmed: 24118248
pmcid: 6496935
doi: 10.1111/cpr.12063
Panella S, Muoio F, Jossen V, et al. Chemically defined xeno-and serum-free cell culture medium to grow human adipose stem cells. Cells. 2021;10(2):466.
pubmed: 33671568
pmcid: 7926673
doi: 10.3390/cells10020466
Park J, Lee JH, Yoon BS, Jun EK, Lee G, Kim IY, You S. Additive effect of bFGF and selenium on expansion and paracrine action of human amniotic fluid-derived mesenchymal stem cells. Stem Cell Res Ther. 2018;9(1):293.
pubmed: 30409167
pmcid: 6225588
doi: 10.1186/s13287-018-1058-z
Schmidt A, Ladage D, Schinköthe T, Klausmann U, Ulrichs C, Klinz FJ, Brixius K, Arnhold S, Desai B, Mehlhorn U, Schwinger RH, Staib P, Addicks K, Bloch W. Basic fibroblast growth factor controls migration in human mesenchymal stem cells. Stem Cells. 2006;24(7):1750–8.
pubmed: 16822883
doi: 10.1634/stemcells.2005-0191
Hosseinzadeh Anvar L, Hosseini-Asl S, Mohammadzadeh-Vardin M, Sagha M. The telomerase activity of selenium-induced human umbilical cord mesenchymal stem cells is associated with different levels of c-Myc and p53 expression. DNA Cell Biol. 2017;36(1):34–41.
pubmed: 27813686
doi: 10.1089/dna.2016.3411
Taurino G, Deshmukh R, Villar VH, Chiu M, Shaw R, Hedley A, Shokry E, Sumpton D, Dander E, D’Amico G, Bussolati O, Tardito S. Mesenchymal stromal cells cultured in physiological conditions sustain citrate secretion with glutamate anaplerosis. Mol Metab. 2022;63:101532.
pubmed: 35752287
pmcid: 9254159
doi: 10.1016/j.molmet.2022.101532
Al Masawa ME, Wan Kamarul Zaman WS, Chua KH. Biosafety evaluation of culture-expanded human chondrocytes with growth factor cocktail: a preclinical study. Sci Rep. 2020;10(1):21583.
pubmed: 33299022
pmcid: 7725787
doi: 10.1038/s41598-020-78395-y
Astori G, Amati E, Bambi F, Bernardi M, Chieregato K, Schäfer R, Sella S, Rodeghiero F. Platelet lysate as a substitute for animal serum for the ex-vivo expansion of mesenchymal stem/stromal cells: present and future. Stem Cell Res Ther. 2016;7(1):93.
pubmed: 27411942
pmcid: 4944312
doi: 10.1186/s13287-016-0352-x
Azouna NB, Jenhani F, Regaya Z, Berraeis L, Othman TB, Ducrocq E, Domenech J. Phenotypical and functional characteristics of mesenchymal stem cells from bone marrow: comparison of culture using different media supplemented with human platelet lysate or fetal bovine serum. Stem Cell Res Ther. 2012;3(1):6.
pubmed: 22333342
pmcid: 3340550
doi: 10.1186/scrt97
Chevallier N, Anagnostou F, Zilber S, Bodivit G, Maurin S, Barrault A, Bierling P, Hernigou P, Layrolle P, Rouard H. Osteoblastic differentiation of human mesenchymal stem cells with platelet lysate. Biomaterials. 2010;31(2):270–8.
pubmed: 19783038
doi: 10.1016/j.biomaterials.2009.09.043
Rhee Y-H, Choi M, Lee H-S, Park C-H, Kim S-M, Yi S-H, Oh S-M, Cha H-J, Chang M-Y, Lee S-H. Insulin concentration is critical in culturing human neural stem cells and neurons. Cell Death Dis. 2013;4(8):e766.
pubmed: 23928705
pmcid: 3763456
doi: 10.1038/cddis.2013.295
Yoo HC, Yu YC, Sung Y, Han JM. Glutamine reliance in cell metabolism. Exp Mol Med. 2020;52(9):1496–516.
pubmed: 32943735
pmcid: 8080614
doi: 10.1038/s12276-020-00504-8
Saito Y, Yoshida Y, Akazawa T, Takahashi K, Niki E. Cell death caused by selenium deficiency and protective effect of antioxidants. J Biol Chem. 2003;278(41):39428–34.
pubmed: 12888577
doi: 10.1074/jbc.M305542200
Gao M, Monian P, Quadri N, Ramasamy R, Jiang X. Glutaminolysis and transferrin regulate ferroptosis. Mol Cell. 2015;59(2):298–308.
pubmed: 26166707
pmcid: 4506736
doi: 10.1016/j.molcel.2015.06.011
Kabat M, Bobkov I, Kumar S, Grumet M. Trends in mesenchymal stem cell clinical trials 2004–2018: is efficacy optimal in a narrow dose range? Stem Cells Transl Med. 2020;9(1):17–27.
pubmed: 31804767
doi: 10.1002/sctm.19-0202
Cao TT, Chen H, Pang M, Xu SS, Wen HQ, Liu B, Rong LM, Li MM. Dose optimization of intrathecal administration of human umbilical cord mesenchymal stem cells for the treatment of subacute incomplete spinal cord injury. Neural Regen Res. 2022;17(8):1785–94.
pubmed: 35017439
pmcid: 8820722
doi: 10.4103/1673-5374.332151
Eydian Z, Mohammad Ghasemi A, Ansari S, Kamali AN, Khosravi M, Momtaz S, Riki S, Rafighdoost L, Entezari HR. Differentiation of multipotent stem cells to insulin-producing cells for treatment of diabetes mellitus: bone marrow- and adipose tissue-derived cells comparison. Mol Biol Rep. 2022;49(5):3539–48.
pubmed: 35107740
doi: 10.1007/s11033-022-07194-7
Ménard C, Dulong J, Roulois D, Hébraud B, Verdière L, Pangault C, Sibut V, Bezier I, Bescher N, Monvoisin C, Gadelorge M, Bertheuil N, Flécher E, Casteilla L, Collas P, Sensebé L, Bourin P, Espagnolle N, Tarte K. Integrated transcriptomic, phenotypic, and functional study reveals tissue-specific immune properties of mesenchymal stromal cells. Stem Cells. 2020;38(1):146–59.
pubmed: 31502731
doi: 10.1002/stem.3077
Nakao M, Inanaga D, Nagase K, Kanazawa H. Characteristic differences of cell sheets composed of mesenchymal stem cells with different tissue origins. Regen Ther. 2019;10(11):34–40.
doi: 10.1016/j.reth.2019.01.002
Donders R, Bogie JFJ, Ravanidis S, Gervois P, Vanheusden M, Marée R, Schrynemackers M, Smeets HJM, Pinxteren J, Gijbels K, Walbers S, Mays RW, Deans R, Van Den Bosch L, Stinissen P, Lambrichts I, Gyselaers W, Hellings N. Human Wharton’s jelly-derived stem cells display a distinct immunomodulatory and proregenerative transcriptional signature compared to bone marrow-derived stem cells. Stem Cells Dev. 2018;27(2):65–84.
pubmed: 29267140
doi: 10.1089/scd.2017.0029
Thakkar UG, Trivedi HL, Vanikar AV, Dave SD. Insulin-secreting adipose-derived mesenchymal stromal cells with bone marrow-derived hematopoietic stem cells from autologous and allogenic sources for type 1 diabetes mellitus. Cytotherapy. 2015;17(7):940–7.
pubmed: 25869301
doi: 10.1016/j.jcyt.2015.03.608
Fekete N, Rojewski MT, Fürst D, Kreja L, Ignatius A, Dausend J, Schrezenmeier H. GMP-compliant isolation and large-scale expansion of bone marrow-derived MSC. PLoS ONE. 2012;7(8):e43255.
pubmed: 22905242
pmcid: 3419200
doi: 10.1371/journal.pone.0043255
Heathman TR, Glyn VA, Picken A, Rafiq QA, Coopman K, Nienow AW, Kara B, Hewitt CJ. Expansion, harvest and cryopreservation of human mesenchymal stem cells in a serum-free microcarrier process. Biotechnol Bioeng. 2015;112(8):1696–707.
pubmed: 25727395
pmcid: 5029583
doi: 10.1002/bit.25582
Crapnell K, Blaesius R, Hastings A, Lennon DP, Caplan AI, Bruder SP. Growth, differentiation capacity, and function of mesenchymal stem cells expanded in serum-free medium developed via combinatorial screening. Exp Cell Res. 2013;319(10):1409–18.
pubmed: 23597555
doi: 10.1016/j.yexcr.2013.04.004
Wu X, Kang H, Liu X, Gao J, Zhao K, Ma Z. Serum and xeno-free, chemically defined, no-plate-coating-based culture system for mesenchymal stromal cells from the umbilical cord. Cell Prolif. 2016;49(5):579–88.
pubmed: 27492579
pmcid: 6496339
doi: 10.1111/cpr.12279
Youssef A, Han VK. Low oxygen tension modulates the insulin-like growth factor-1 or -2 signaling via both insulin-like growth factor-1 receptor and insulin receptor to maintain stem cell Identity in placental mesenchymal stem cells. Endocrinology. 2016;157(3):1163–74.
pubmed: 26760116
doi: 10.1210/en.2015-1297
Youssef A, Iosef C, Han VK. Low-oxygen tension and IGF-I promote proliferation and multipotency of placental mesenchymal stem cells (PMSCs) from different gestations via distinct signaling pathways. Endocrinology. 2014;155(4):1386–97.
pubmed: 24506070
doi: 10.1210/en.2013-1842
Ben Azouna N, Jenhani F, Regaya Z, Berraeis L, Ben Othman T, Ducrocq E, Domenech J. Phenotypical and functional characteristics of mesenchymal stem cells from bone marrow: comparison of culture using different media supplemented with human platelet lysate or fetal bovine serum. Stem Cell Res Ther. 2012;3(1):6.
pubmed: 22333342
doi: 10.1186/scrt97
Stern-Straeter J, Bonaterra GA, Juritz S, Birk R, Goessler UR, Bieback K, Bugert P, Schultz J, Hörmann K, Kinscherf R, Faber A. Evaluation of the effects of different culture media on the myogenic differentiation potential of adipose tissue- or bone marrow-derived human mesenchymal stem cells. Int J Mol Med. 2014;33(1):160–70.
pubmed: 24220225
doi: 10.3892/ijmm.2013.1555